# Cervical cancer screening in Australia and New Zealand

# 1. Introduction

### 5. Useful Links

a) Australia

Both long-form and short-form versions of the Australian National Cervical Screening Guideline are available at the following link: <a href="https://wiki.cancer.org.au/australia/Guidelines:Cervical\_cancer/Screening">https://wiki.cancer.org.au/australia/Guidelines:Cervical\_cancer/Screening</a>

a) New Zealand

Details of the NZ NCSP can be found on the Ministry of Health website.

https://www.nsu.govt.nz/health-professionals/national-cervical-screening-programme/clinical-practice-guidelines-cervical

The MOH website also provides updates on the roll out of the planned primary HPV screening program.

## 6. References

- Ronco G, Dillner J, Elfström KM, Tunesi S, Snijders PJ, Arbyn M, et al. <u>Efficacy of HPV-based screening</u> for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 2014 Feb 8;383(9916):524-32.
- 2. Franceschi S, Denny L, Irwin KL, Jeronimo J, Lopalco PL, Monsonego J, et al. *Eurogin 2010 roadmap* on cervical cancer prevention. Int J Cancer 2011 Jun 15;128(12):2765-74.
- 3. Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, et al. <u>HPV screening</u> <u>for cervical cancer in rural India.</u> N Engl J Med 2009 Apr 2;360(14):1385-94.

7.

## **Appendices**

#### Appendix A Women's Health Committee Membership

Name	Position on Committee		
Professor Yee Leung	Chair and Board Member		
Dr Gillian Gibson	Deputy Chair, Gynaecology		
Dr Scott White	Deputy Chair, Obstetrics		
Associate Professor Ian Pettigrew	Member and EAC Representative		
Dr Kristy Milward	Member and Councillor		
Dr Will Milford ScoiFII 11.51127(for)9.	994 ēmbleera and CCC ou no id libror		

Dr E7 0 0 1 77.6641no7 10 0y238 6001 4D5-OKSE

## Appendix B Overview of the development and review process for this statement

i. Steps in developing and updating this statement

This statement was originally developed in November 2006 and was most recently amended in July 2020. The Worrer(st-leath Committee carried out the following steps in reviewing this statement:

Declarations of interest were sought from all members prior to reviewing this statement.

An updated literature search was undertaken.

At the July 2020 committee meeting, the existing consensus-based recommendations were reviewed and updated (where appropriate) based on the available body of evidence and clinical expertise. Recommendations were graded as set out below in Appendix B part iii)

ii. Declaration of interest process and management

Declaring interests is essential in order to prevent any potent

#### Appendix C Full Disclaimer

This information is intended to provide general advice to practitioners, and should not be relied on as a substitute for proper assessment with respect to the particular circumstances of each case and the needs of any patient.

This information has been prepared having regard to general circumstances. It is the responsibility of each practitioner to have regard to the particular circumstances of each case. Clinical management should be responsive to the needs of the individual patient and the particular circumstances of each case.

This information has been prepared having regard to the information available at the time of its preparation, and each practitioner should have regard to relevant information, research or material which may have been published or become available subsequently.

Whilst the College endeavours to ensure that information is accurate and current at the time of preparation, it takes no responsibility for matters arising from changed circumstances or information or material that may have become subsequently available.